References
Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of ator-vastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718.
Sacks FM: Lipid-lowering therapy in acute coronary syndromes. JAMA 2001, 285:1758–1760.
Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.
Freedman JE: Antioxidant versus lipid-altering therapy--some answers, more questions. N Engl J Med 2001, 345:1636–1637.
Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.
Rader DJ: A new feature on the cholesterol-lowering landscape. Nat Med 2001, 7:1282–1284.
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23–33.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.
Hutchison SJ, Reitz MS, Sudhir K, et al.: Chronic dietary L-arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits. Hypertension 1997, 29:1186–1191.
Rights and permissions
About this article
Cite this article
Wilson, P.W.F. Clinical trials report. Curr Cardiol Rep 4, 485–487 (2002). https://doi.org/10.1007/s11886-002-0111-8
Issue Date:
DOI: https://doi.org/10.1007/s11886-002-0111-8